Yes

Corticosteroid, Topical

Relief of susceptible inflammatory dermatosis [low, medium, high potency topical corticosteroid]

C

Fungal infection, hypersensitivity to fluocinolone or any component, TB of skin, herpes (including varicella)

Adverse systemic effects may occur when used on large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in infants or small children. Infants and small children may be more susceptible to adrenal axis suppression from topical corticosteroid therapy.

<1%: Acne, hypopigmentation, allergic dermatitis, maceration of the skin, skin atrophy, folliculitis, hypertrichosis, dry skin, itching, HPA suppression, Cushing's syndrome, growth retardation, burning, irritation, secondary infection

When consumed in excessive quantities, systemic hypercorticism and adrenal suppression may occur; in those cases, discontinuation and withdrawal of the corticosteroid should be done judiciously

No data reported

A synthetic corticosteroid which differs structurally from triamcinolone acetonide in the presence of an additional fluorine atom in the 6-alpha position on the steroid nucleus. The mechanism of action for all topical corticosteroids is not well defined, however, is believed to be a combination of three important properties: anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions.

Absorption: Dependent on strength of preparation, amount applied,and nature of skin at application site; ranges from ~1% in thick stratum corneum areas (palms, soles, elbows, etc) to 36% in areas of thinnest stratum corneum (face, eyelids, etc); increased absorption in areas of skin damage, inflammation, or occlusion

Distribution: Throughout the local skin; absorbed drug is distributed rapidly into muscle, liver, skin, intestines, and kidneys

Metabolism: Primarily in the skin; small amount absorbed into systemic circulation is metabolized primarily in the liver to inactive compounds

Elimination: By the kidneys primarily as glucuronides and sulfate, but also as unconjugated products; small amounts of metabolites are excreted in feces

Children and Adults: Topical: Apply a thin layer to affected area 2-4 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.

No information available to require special precautions

No effects or complications reported

A thin film of cream or ointment is effective; do not overuse; do not use tight-fitting diapers or plastic pants on children being treated in the diaper area; use only as prescribed, and for no longer than the period prescribed; apply sparingly in light film; rub in lightly; avoid contact with eyes; notify physician if condition being treated persists or worsens

Use sparingly

Cream, as acetonide: 0.01% (15 g, 60 g); 0.025% (15 g, 60 g)

Flurosyn®, Synalar®: 0.01% (15 g, 30 g, 60 g, 425 g)

Flurosyn®, Synalar®, Synemol®: 0.025% (15 g, 60 g, 425 g)

Synalar-HP®: 0.2% (12 g)

Ointment, topical, as acetonide: 0.025% (15 g, 60 g)

Flurosyn®, Synalar®: 0.025% (15 g, 30 g, 60 g, 425 g)

Oil, as acetonide (Derma-Smoothe/FS®): 0.01% (120 mL)

Shampoo, as acetonide (FS Shampoo®): 0.01% (180 mL)

Solution, topical, as acetonide: 0.01% (20 mL, 60 mL)

Fluonid®, Synalar®: 0.01% (20 mL, 60 mL)